Rohto Pharmaceutical Co.,Ltd.

Symbol: 4527.T

JPX

3200

JPY

Market price today

  • 23.2296

    P/E Ratio

  • 0.8870

    PEG Ratio

  • 730.04B

    MRK Cap

  • 0.01%

    DIV Yield

Rohto Pharmaceutical Co.,Ltd. (4527-T) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.58%

Operating Profit Margin

0.15%

Net Profit Margin

0.12%

Return on Assets

0.09%

Return on Equity

0.14%

Return on Capital Employed

0.16%

Company general description and statistics

Sector: Consumer Defensive
Industry: Household & Personal Products
CEO:Mr. Yamada Kunio
Full-time employees:7176
City:Osaka
Address:1-8-1, Tatsumi-nishi
IPO:2001-01-04
CIK:

Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin; medicine for internal use, such as digestive and herbal medicines; oral medicines comprising gastrointestinal medicines, herbal medicines, and supplements; non-prescription medicines; and beauty counters that provide beauty and health services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. Rohto Pharmaceutical Co.,Ltd. was founded in 1899 and is headquartered in Osaka, Japan.

General Outlook

When we look at how much money they make before expenses, they keep 0.582% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.154%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.117%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.090% return, is a testament to Rohto Pharmaceutical Co.,Ltd.'s adeptness in optimizing resource deployment. Rohto Pharmaceutical Co.,Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.137%. Furthermore, the proficiency of Rohto Pharmaceutical Co.,Ltd. in capital utilization is underscored by a remarkable 0.157% return on capital employed.

Stock Prices

Rohto Pharmaceutical Co.,Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $3092, while its low point bottomed out at $3051. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Rohto Pharmaceutical Co.,Ltd.'s stock market.

Liquidity Ratios

Analyzing 4527.T liquidity ratios reveals its financial health of the firm. The current ratio of 256.11% gauges short-term asset coverage for liabilities. The quick ratio (185.19%) assesses immediate liquidity, while the cash ratio (97.90%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio256.11%
Quick Ratio185.19%
Cash Ratio97.90%

Profitability Ratios

4527.T profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 15.68% underscores its earnings before tax deductions. The effective tax rate stands at 24.69%, revealing its tax efficiency. The net income per EBT, 74.75%, and the EBT per EBIT, 101.75%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 15.41%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin15.68%
Effective Tax Rate24.69%
Net Income per EBT74.75%
EBT per EBIT101.75%
EBIT per Revenue15.41%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.56, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 361.03% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding185
Days of Inventory Outstanding161
Operating Cycle261.65
Days of Payables Outstanding74
Cash Conversion Cycle187
Receivables Turnover3.61
Payables Turnover4.92
Inventory Turnover2.27
Fixed Asset Turnover3.85
Asset Turnover0.77

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 74.69, and free cash flow per share, 74.69, depict cash generation on a per-share basis. The cash per share value, 358.89, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.06, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share74.69
Free Cash Flow per Share74.69
Cash per Share358.89
Operating Cash Flow Sales Ratio0.06
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio1.77
Short Term Coverage Ratio3.91

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2.82%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.04, we discern the balance between debt and equity financing. The long-term debt to capitalization, 2.15%, and total debt to capitalization, 3.86%, ratios shed light on its capital structure. An interest coverage of 174.35 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio2.82%
Debt Equity Ratio0.04
Long Term Debt to Capitalization2.15%
Total Debt to Capitalization3.86%
Interest Coverage174.35
Cash Flow to Debt Ratio1.77
Company Equity Multiplier1.43

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 10.27%, indicates top-line expansion, while the gross profit growth, 9.15%, reveals profitability trends. EBIT growth, 27.66%, and operating income growth, 27.66%, offer insights into operational profitability progression. The net income growth, 25.53%, showcases bottom-line expansion, and the EPS growth, 25.53%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth10.27%
Gross Profit Growth9.15%
EBIT Growth27.66%
Operating Income Growth27.66%
Net Income Growth25.53%
EPS Growth25.53%
EPS Diluted Growth25.54%
Dividends per Share Growth15.41%
Operating Cash Flow Growth36.20%
Free Cash Flow Growth64.08%
10-Year Revenue Growth per Share59.95%
5-Year Revenue Growth per Share16.06%
3-Year Revenue Growth per Share8.59%
10-Year Operating CF Growth per Share68.19%
5-Year Operating CF Growth per Share42.08%
3-Year Operating CF Growth per Share25.19%
10-Year Net Income Growth per Share167.92%
5-Year Net Income Growth per Share125.96%
3-Year Net Income Growth per Share114.28%
10-Year Shareholders Equity Growth per Share96.67%
5-Year Shareholders Equity Growth per Share39.44%
3-Year Shareholders Equity Growth per Share35.68%
10-Year Dividend per Share Growth per Share87.54%
5-Year Dividend per Share Growth per Share36.37%
3-Year Dividend per Share Growth per Share36.41%
Receivables Growth6.74%
Inventory Growth20.06%
Asset Growth21.63%
Book Value per Share Growth14.35%
Debt Growth164.02%
R&D Expense Growth10.59%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.99, and the price to book ratio, 2.99, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.72, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 42.12, and price to operating cash flows, 42.12, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.99
Price to Book Ratio2.99
Price to Sales Ratio2.72
Price Cash Flow Ratio42.12
Price Earnings to Growth Ratio0.89
Enterprise Value Multiple17.66
Price Fair Value2.99
Price to Operating Cash Flow Ratio42.12
Price to Free Cash Flows Ratio42.12
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Rohto Pharmaceutical Co.,Ltd. (4527.T) on the JPX in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 23.230 in 2024.

What is the ticker symbol of Rohto Pharmaceutical Co.,Ltd. stock?

The ticker symbol of Rohto Pharmaceutical Co.,Ltd. stock is 4527.T.

What is company IPO date?

IPO date of Rohto Pharmaceutical Co.,Ltd. is 2001-01-04.

What is company current share price?

Current share price is 3200.000 JPY.

What is stock market cap today?

The market cap of stock today is 730043324800.000.

What is PEG ratio in 2024?

The current 0.887 is 0.887 in 2024.

What is the number of employees in 2024?

In 2024 the company has 7176.